European regulators have recommended approval of a groundbreaking HIV prevention drug that could significantly reduce transmission rates. The European Medicines Agency (EMA) endorsed lenacapavir, an injectable treatment to be marketed in Europe as Yeytuo, marking the first time a twice-yearly HIV preventive has received such backing within the European Union.
The drug, which has already been approved in the U.S. under the name Yeztugo, has shown exceptional effectiveness in preventing HIV infections across both men and women in recent clinical studies. Its long-acting formula only requires two injections per year, making it a potential game-changer for individuals who struggle with the daily commitment of oral PrEP (pre-exposure prophylaxis) medications.
Once the European Commission gives final authorization, lenacapavir will be available throughout EU member states, as well as in countries like Norway, Iceland, and Liechtenstein. Health experts believe this approval could dramatically expand access to HIV prevention, particularly among communities with limited healthcare access or those facing stigma around daily pill use.
Pharmaceutical company Gilead Sciences, which manufactures the drug, has also committed to licensing generic production in roughly 120 lower-income countries. Advocates welcomed the step but continue to urge expanded global availability, especially in underserved regions beyond the current distribution plans.
